Tm Bioscience Licenses Tm-100 Universal DNA Microarray Technology and Hairpin Capture Probes to Luminex

- Luminex and Tm Bioscience Also Enter Into Strategic Partnership for Tm To

Develop and Commercialize Products for Use on the Luminex LabMAP System -



Apr 02, 2001, 01:00 ET from Luminex Corporation and Tm Bioscience Corporation

    AUSTIN, Texas and TORONTO, April 2 /PRNewswire/ --
 Luminex Corporation (Nasdaq: LMNX) and Tm Bioscience Corporation (CDNX: TMC)
 announced today that Tm has licensed to Luminex two key components of Tm
 Bioscience's microarray technology.  Luminex intends to combine these
 technologies with its proprietary LabMAP(TM) system to provide an accurate and
 economical platform for genomic analysis.
     In a related agreement Tm has also entered into a multi-year strategic
 partnership with Luminex, granting Tm rights to develop and market diagnostic
 products based on Luminex's LabMAP technology.
     "We believe that the Luminex LabMAP system is the premiere microarray
 platform available today," said Greg Hines, CEO of Tm.  "Since the validation
 of our Tm-100 Universal microarray was announced in November, it has been a
 priority to secure access to the Luminex platform.  The combination of the Tm
 Bioscience technologies and the Luminex platform is expected to provide
 powerful genomic tools for use in drug discovery, disease management and
 diagnosis.  We expect the strategic partnership and licensing agreement will
 provide Tm with significant revenues in a microarray market expected to grow
 to over $5 billion in the next five years.  Tm Bioscience is now well
 positioned to exploit this market opportunity."
     "Through our license agreement with Tm Bioscience we expect to develop and
 produce a universal nucleic acid array with our microspheres," commented Mark
 Chandler, CEO of Luminex.  "This product should make the genetic analyses
 simple to develop and perform and could obviate the need for the complex and
 expensive microfabricated devices that are currently being developed for the
 genetic testing market.  We believe that employing the unique capture tags
 provided by Tm on the Luminex microsphere surface should allow up to
 10,000 distinct genetic sequences to be analyzed in approximately 30 minutes
 at a very competitive cost.  We are hopeful that this approach will streamline
 nucleic acid assay development and offer additional flexibility to our
 strategic partners and end-users."
     Luminex has obtained exclusive rights to Tm's Universal tags and hairpin
 capture probes for applications involving bead-based microarrays.  The license
 agreement provides Tm with milestone payments and royalties based on sales of
 products incorporating Tm's technology.  Luminex will manufacture and market
 the new Luminex universal microarray.
     Luminex's LabMAP technology is a proprietary biological testing platform
 that can perform multiple assays simultaneously on a single drop of fluid,
 with the capacity for small, medium and high throughput applications.  This
 system combines the use of low-cost microsphere-based assays with diode
 lasers, advanced digital signal processors and proprietary software to offer
 greater speed, precision and flexibility over current bioassay technologies
     The Tm 100 Universal microarray includes a unique set of DNA tag sequences
 that have been proven by Tm to hybridize without cross-talk in the Luminex
 LabMAP system.  The system should minimize if not eliminate false positive and
 false negative results from genomic tests.  This will be important for
 FDA-approved diagnostic tests as well as pre-clinical (i.e. toxicity studies)
 trials in pharmaceutical development.  Tm's unique Hairpin Capture Probes
 improve the kinetics of DNA microarrays.  This will provide end users with a
 more rapid test result especially when the volume of the patient's test sample
 is small.
 
     About Luminex Corporation
     Luminex Corporation develops, manufactures and markets proprietary
 biological testing technologies with applications throughout the life sciences
 industry.  The company's LabMAP(TM) system is an open-architecture,
 multi-analyte technology platform that delivers fast, accurate and
 cost-effective bioassay results to markets as diverse as pharmaceutical drug
 discovery, clinical diagnostics and biomedical research, including the
 genomics and proteomics research markets.  The company's LabMAP(TM) technology
 is sold worldwide and is already in use in leading research laboratories as
 well as major pharmaceutical, diagnostic and biotechnology companies.  Further
 information on Luminex Corporation or LabMAP(TM) can be obtained on the
 Internet at http://www.luminexcorp.com.
 
     About Tm Bioscience Corporation
     Tm Bioscience is an emerging Canadian genomics company developing and
 commercializing proprietary DNA-based technologies for application in biochips
 (microarrays), diagnostics and genomic analysis.  The Company offers
 pharmaceutical and biotechnology companies the ability to develop novel
 DNA-based products for medical and research applications.  Tm Bioscience is
 based in Toronto, Ontario.  Additional information about Tm Bioscience can be
 found at www.tmbioscience.com or by contacting Alan Coley or Jay Hussey.
     Statements made in this press release that state Luminex's or Tm
 Bioscience's management's intentions, plans, beliefs, expectations or
 predictions of future events are forward-looking statements.  It is important
 to note that the companies' actual results or performance could differ
 materially from those projected in such forward-looking statements.  Factors
 that could cause such actual results or performance to differ materially
 include risks and uncertainties relating to market demand and acceptance, the
 dependence on strategic partners for development and distribution of products,
 competition, the ability to scale-up manufacturing operations, potential
 shortages of components and the timing of regulatory approvals, as well as the
 risks discussed under the heading "Factors That May Affect Future Results" in
 Luminex's Form 10-K for the year ended December 31, 2000 as filed with the
 Securities and Exchange Commission.  The forward-looking statements contained
 herein represent the judgment of Luminex as of the date of this release, and
 Luminex disclaims any intent or obligation to update or revise such
 forward-looking statements to reflect any change in Luminex's expectations
 with regard thereto or any change in events, conditions or circumstances on
 which such statements are based.
 
      Tm Bioscience Contact:
      Alan Coley
      Vice President, Corporate Communications
      416-593-4323
      acoley@tmbioscience.com
      Jay Hussey
      Investor and Media Inquiries
      416-815-0700 ext.225
      jhussey@equicomgroup.com
 
      Luminex Contact:
      John Porter
      Director of Business Development
      512-219-8020
      jporter@luminexcorp.com
 
     The Canadian Venture Exchange has not reviewed and does not accept
 responsibility for the adequacy or accuracy of this release.
 
 

SOURCE Luminex Corporation and Tm Bioscience Corporation
    AUSTIN, Texas and TORONTO, April 2 /PRNewswire/ --
 Luminex Corporation (Nasdaq: LMNX) and Tm Bioscience Corporation (CDNX: TMC)
 announced today that Tm has licensed to Luminex two key components of Tm
 Bioscience's microarray technology.  Luminex intends to combine these
 technologies with its proprietary LabMAP(TM) system to provide an accurate and
 economical platform for genomic analysis.
     In a related agreement Tm has also entered into a multi-year strategic
 partnership with Luminex, granting Tm rights to develop and market diagnostic
 products based on Luminex's LabMAP technology.
     "We believe that the Luminex LabMAP system is the premiere microarray
 platform available today," said Greg Hines, CEO of Tm.  "Since the validation
 of our Tm-100 Universal microarray was announced in November, it has been a
 priority to secure access to the Luminex platform.  The combination of the Tm
 Bioscience technologies and the Luminex platform is expected to provide
 powerful genomic tools for use in drug discovery, disease management and
 diagnosis.  We expect the strategic partnership and licensing agreement will
 provide Tm with significant revenues in a microarray market expected to grow
 to over $5 billion in the next five years.  Tm Bioscience is now well
 positioned to exploit this market opportunity."
     "Through our license agreement with Tm Bioscience we expect to develop and
 produce a universal nucleic acid array with our microspheres," commented Mark
 Chandler, CEO of Luminex.  "This product should make the genetic analyses
 simple to develop and perform and could obviate the need for the complex and
 expensive microfabricated devices that are currently being developed for the
 genetic testing market.  We believe that employing the unique capture tags
 provided by Tm on the Luminex microsphere surface should allow up to
 10,000 distinct genetic sequences to be analyzed in approximately 30 minutes
 at a very competitive cost.  We are hopeful that this approach will streamline
 nucleic acid assay development and offer additional flexibility to our
 strategic partners and end-users."
     Luminex has obtained exclusive rights to Tm's Universal tags and hairpin
 capture probes for applications involving bead-based microarrays.  The license
 agreement provides Tm with milestone payments and royalties based on sales of
 products incorporating Tm's technology.  Luminex will manufacture and market
 the new Luminex universal microarray.
     Luminex's LabMAP technology is a proprietary biological testing platform
 that can perform multiple assays simultaneously on a single drop of fluid,
 with the capacity for small, medium and high throughput applications.  This
 system combines the use of low-cost microsphere-based assays with diode
 lasers, advanced digital signal processors and proprietary software to offer
 greater speed, precision and flexibility over current bioassay technologies
     The Tm 100 Universal microarray includes a unique set of DNA tag sequences
 that have been proven by Tm to hybridize without cross-talk in the Luminex
 LabMAP system.  The system should minimize if not eliminate false positive and
 false negative results from genomic tests.  This will be important for
 FDA-approved diagnostic tests as well as pre-clinical (i.e. toxicity studies)
 trials in pharmaceutical development.  Tm's unique Hairpin Capture Probes
 improve the kinetics of DNA microarrays.  This will provide end users with a
 more rapid test result especially when the volume of the patient's test sample
 is small.
 
     About Luminex Corporation
     Luminex Corporation develops, manufactures and markets proprietary
 biological testing technologies with applications throughout the life sciences
 industry.  The company's LabMAP(TM) system is an open-architecture,
 multi-analyte technology platform that delivers fast, accurate and
 cost-effective bioassay results to markets as diverse as pharmaceutical drug
 discovery, clinical diagnostics and biomedical research, including the
 genomics and proteomics research markets.  The company's LabMAP(TM) technology
 is sold worldwide and is already in use in leading research laboratories as
 well as major pharmaceutical, diagnostic and biotechnology companies.  Further
 information on Luminex Corporation or LabMAP(TM) can be obtained on the
 Internet at http://www.luminexcorp.com.
 
     About Tm Bioscience Corporation
     Tm Bioscience is an emerging Canadian genomics company developing and
 commercializing proprietary DNA-based technologies for application in biochips
 (microarrays), diagnostics and genomic analysis.  The Company offers
 pharmaceutical and biotechnology companies the ability to develop novel
 DNA-based products for medical and research applications.  Tm Bioscience is
 based in Toronto, Ontario.  Additional information about Tm Bioscience can be
 found at www.tmbioscience.com or by contacting Alan Coley or Jay Hussey.
     Statements made in this press release that state Luminex's or Tm
 Bioscience's management's intentions, plans, beliefs, expectations or
 predictions of future events are forward-looking statements.  It is important
 to note that the companies' actual results or performance could differ
 materially from those projected in such forward-looking statements.  Factors
 that could cause such actual results or performance to differ materially
 include risks and uncertainties relating to market demand and acceptance, the
 dependence on strategic partners for development and distribution of products,
 competition, the ability to scale-up manufacturing operations, potential
 shortages of components and the timing of regulatory approvals, as well as the
 risks discussed under the heading "Factors That May Affect Future Results" in
 Luminex's Form 10-K for the year ended December 31, 2000 as filed with the
 Securities and Exchange Commission.  The forward-looking statements contained
 herein represent the judgment of Luminex as of the date of this release, and
 Luminex disclaims any intent or obligation to update or revise such
 forward-looking statements to reflect any change in Luminex's expectations
 with regard thereto or any change in events, conditions or circumstances on
 which such statements are based.
 
      Tm Bioscience Contact:
      Alan Coley
      Vice President, Corporate Communications
      416-593-4323
      acoley@tmbioscience.com
      Jay Hussey
      Investor and Media Inquiries
      416-815-0700 ext.225
      jhussey@equicomgroup.com
 
      Luminex Contact:
      John Porter
      Director of Business Development
      512-219-8020
      jporter@luminexcorp.com
 
     The Canadian Venture Exchange has not reviewed and does not accept
 responsibility for the adequacy or accuracy of this release.
 
 SOURCE  Luminex Corporation and Tm Bioscience Corporation